23 Jul, 2026
According to Straits Research, the global insulin market size was valued at $21.13 billion in 2025 and is expected to reach $29.01 billion by 2034, registering a CAGR of 3.63% during the forecast period (2026–2034).
The market growth is primarily attributed to the rising prevalence of diabetes and continuous innovations in insulin formulations, including long-acting and rapid-acting therapies, which improve patient adherence and clinical outcomes. In addition, the expansion of production capacity by leading pharmaceutical companies is driving growth in the global insulin market. For instance, in December 2024, Sanofi announced it planned to invest USD 1.1 billion in constructing a new insulin production facility in Beijing's Economic and Technological Development Zone, marking its largest investment in China to date. This facility was Sanofi's fourth production and supply center in the country, enhancing local insulin production capacity and meeting growing demand. Such expansion strengthened the global insulin supply chain, improved accessibility, and supported the market’s sustained growth in response to increasing diabetes prevalence. However, the insulin market faced a major restraint due to its high cost, which remained a significant barrier for patients in low and middle-income countries. Despite of these challenges, the market presented significant opportunities, such as the growing adoption of smart insulin delivery devices, which represented a significant opportunity for the global insulin market. These connected systems, such as smart pens, patch pumps, and closed-loop automation, harness AI-driven insights to optimize dosing and improve patient adherence. Furthermore, increasing awareness and acceptance of these advanced technologies, especially in developed regions, is expected to expand the widespread adoption and create new avenues for market growth.
sales@straitsresearch.com